Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2013 Q1- Text added to 2013 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
AbbVie, accrual, acute, AMPLIFY, apixaban, arbitration, arm, Atripla, Avalide, BLA, Circulation, concurrent, concurrently, confirmed, cough, deep, Delestrogen, dexamethasone, difficult, dismissing, earlier, elotuzumab, England, Estradiol, exceed, free, gap, Gleevec, good, history, Humira, hypercholesterolemia, IIa, infarction, ipilimumab, ischemic, Ixempra, journal, Kombiglyze, Komboglyze, Labour, lenalidomide, median, modified, Mucomyst, myeloma, myocardial, Onglyza, online, Ono, ORR, OTC, Ovcon, PDUFA, PFS, pilot, precautionary, prespecified, published, pulmonary, Questran, randomized, recall, Recothrom, Reglan, resupply, sequentially, shrank, subgroup, submitted, Symlin, trended, Truvada, vein
Removed:
ade, andAtripla, andForxiga, andKomboglyze, andOrencia, andOvcon, andSustiva, andTruvada, approach, arterial, bothKombiglyze, buying, certainAbilify, China, combiningSustiva, commercializeAtripla, copromoteAbilify, coveringBaraclude, coveringSprycel, coveringSustiva, forAtripla, forBaraclude, forForxiga, forPlavix, forSprycel, includesSustiva, includingGleevec, inPlavix, liver, ofAbilify, ofAtripla, ofBaraclude, ofErbitux, ofOrencia, ofPlavix, ofSprycel, ofTruvada, pediatric, pendingPlavix, point, polymerase, reinvest, reliable, Russia, sellAbilify, strongest, terminate, thrombotic, toErbitux, usingPlavix, usingReglan, whenAbilify
Valuein 2013 Q1 filing- Value in 2013 Q2 filing
Original filings
Filing view